{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:26:50Z","timestamp":1792272410268,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU), allergic asthma, and chronic rhinosinusitis with nasal polyps. While self-administration is licensed in Ireland, reimbursement restrictions require hospital-based delivery, placing significant burdens on patients and healthcare services.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To evaluate patient perspectives on hospital-based administration of Omalizumab, and assess the practical, financial, and environmental implications of current practices, alongside interest in transitioning to home-based therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cross-sectional survey was conducted among patients receiving Omalizumab in a tertiary referral hospital between December 2024 and January 2025. Eligible participants (n=49) completed a 20- question anonymous questionnaire exploring demographics, treatment burden, and attitudes toward home therapy. Cost data were obtained from institutional finance records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 49 respondents (98% response rate), 46.9% reported personal costs of \u20ac11\u2013\u20ac50 per hospital visit, with some incurring over \u20ac1,300 annually. Over one quarter (26.5%) missed more than 11 workdays per year due to treatment. Most travelled by private vehicle, generating an estimated 2.1 tonnes of CO\u2082 annually. A majority (77.5%) would prefer home therapy, citing convenience, flexibility, and reduced financial burden. Annual institutional costs for hospital-based administration of Omalizumab exceeded \u20ac1 million, excluding drug expenditure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hospital-based administration of Omalizumab imposes significant patient and system-level costs. These findings support a transition to reimbursed self-administration at home, which may improve patient satisfaction, reduce absenteeism, minimise environmental impact, and achieve considerable healthcare savings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11845-025-03978-5","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:37:30Z","timestamp":1750826250000},"page":"793-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The patient perspective on use of Omalizumab in the in-hospital setting"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2958-8106","authenticated-orcid":false,"given":"Lara","family":"Dungan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"11","key":"3978_CR1","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/clt2.70002","volume":"14","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Muraro A, Nurmatov U et al (2024) GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management. Clin Transl Allergy 14(11). https:\/\/doi.org\/10.1002\/clt2.70002","journal-title":"Clin Transl Allergy"},{"issue":"11","key":"3978_CR2","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.waojou.2019.100079","volume":"12","author":"TA Popov","year":"2019","unstructured":"Popov TA et al (2019) Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. World Allergy Organ J 12(11). https:\/\/doi.org\/10.1016\/j.waojou.2019.100079","journal-title":"World Allergy Organ J"},{"key":"3978_CR3","unstructured":"Novartis Receives European Commission Approval for Self-Administration of Xolair\u00ae across All Indications (December 13, 2018). PDF available at: https:\/\/novartis.gcs-web.com\/static-files\/4fc6c152-dec0-4acf-b39a-a2d1b88d7056 (Accessed: 01 April 2025)."},{"issue":"1","key":"3978_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rmed.2013.10.026","volume":"108","author":"R Buhl","year":"2014","unstructured":"Buhl R and others (2014) Eligibility for treatment with omalizumab in Italy and Germany. Respir Med 108(1):50\u201356. https:\/\/doi.org\/10.1016\/j.rmed.2013.10.026","journal-title":"Respir Med"},{"issue":"12","key":"3978_CR5","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.jaip.2023.08.033","volume":"11","author":"J Litovsky","year":"2023","unstructured":"Litovsky J, Hacard F, T\u00e9tart F et al (2023) Omalizumab drug survival in chronic urticaria: a retrospective multicentric French study. J Allergy Clin Immunol Pract 11(12):3752\u201362. https:\/\/doi.org\/10.1016\/j.jaip.2023.08.033","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"3978_CR6","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.waojou.2021.100610","volume":"14","author":"Z Zhao","year":"2021","unstructured":"Zhao Z et al (2021) Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J 14(11):100610. https:\/\/doi.org\/10.1016\/j.waojou.2021.100610","journal-title":"World Allergy Organ J"},{"issue":"10","key":"3978_CR7","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.waojou.2021.100587","volume":"14","author":"C King","year":"2021","unstructured":"King C et al (2021) Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective. World Allergy Organ J 14(10):100587. https:\/\/doi.org\/10.1016\/j.waojou.2021.100587","journal-title":"World Allergy Organ J"},{"issue":"2","key":"3978_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/a-1069-0900","volume":"74","author":"H Timmermann","year":"2020","unstructured":"Timmermann H, Mail\u00e4nder C (2020) Home self-administration of biologics - a German survey among omalizumab-treated patients with severe asthma and their treating physicians. Pneumologie 74(2):103\u2013111. https:\/\/doi.org\/10.1055\/a-1069-0900","journal-title":"Pneumologie"},{"issue":"1","key":"3978_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40359-023-01284-2","volume":"11","author":"J Donnelly","year":"2023","unstructured":"Donnelly J, Ridge K, O\u2019Donovan R et al (2023) Psychosocial factors and chronic spontaneous urticaria: a systematic review. BMC Psychol 11(1):239. https:\/\/doi.org\/10.1186\/s40359-023-01284-2","journal-title":"BMC Psychol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03978-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03978-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03978-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:18:59Z","timestamp":1752898739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03978-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3978"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03978-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by the Beaumont Hospital Ethics (Medical Research) Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}